Navigation Links
Proteon Initiates Second Phase 1/2 Clinical Study of PRT-201 in Hemodialysis Patients
Date:11/23/2009

WALTHAM, Mass., Nov. 23 /PRNewswire/ -- Proteon Therapeutics, Inc., has initiated a Phase 1/2 human clinical study of its lead product, PRT-201, in end-stage renal disease (ESRD) patients undergoing surgery for arteriovenous graft (AVG) creation. The AVG study represents Proteon's second human clinical study in hemodialysis patients, previously announcing the initiation of a Phase 1/2 study of PRT-201 in ESRD patients undergoing surgery for arteriovenous fistula (AVF) creation earlier this year. Proteon also announces the appointment of board member Gregory D. Phelps as Chairman of the Board of Directors.

"Our lead product, PRT-201, represents a highly innovative approach to addressing the significant medical challenges associated with vascular access in ESRD patients, and we are excited about the progress that we have made to date," said Timothy P. Noyes, President and CEO of Proteon. "We are now actively enrolling patients into two separate double-blind, placebo-controlled Phase 1/2 human clinical trials utilizing PRT-201 in AVF and AVG surgical settings. Greg's appointment to Chairman of the Board provides our team with even greater access to his wealth of strategic and operational experience at an important stage of Proteon's development."

"I am very happy to assume the role as Chairman of Proteon and to take a more active role in the progress of Proteon," said Greg Phelps. "I have enjoyed working with Tim Noyes, the Board and the management team over the last two years, and Proteon's development programs are exceptionally promising."

Greg Phelps has more than 30 years experience in the medical products and biotechnology fields, where he has held Chief Executive Officer, Board Director and senior management positions in several companies. He is co-founder and partner of Red Sky Partners LLC, a team of experienced healthcare executives focused on new ventures in clinical development and strategic consulting in the
'/>"/>

Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Echo Therapeutics Initiates Clinical Study of its New One-Piece Symphony(TM) tCGM Biosensor in Type 1 and Type 2 Diabetic Patients
2. Incept BioSystems Initiates First Human Clinical Trial of its SMART Embryo Culture System for In Vitro Fertilization (IVF)
3. BioMarin Initiates Phase 2 Clinical Study of PEG-PAL in PKU
4. Lexicon Completes Phase 1 Clinical Trial and Initiates Phase 2 Clinical Trial of LX4211 in Patients With Type 2 Diabetes
5. LigoCyte Pharmaceuticals Initiates a Randomized, Double Blind, Placebo Controlled Norovirus Vaccine Study Including Live Virus Challenge
6. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
7. Terumo Cardiovascular Systems Initiates U.S. Clinical Trial for Anaconda(TM) AAA Stent Graft System
8. Cytokine PharmaSciences Initiates Phase I Study of Oral Anti-Inflammatory Agent, CPSI-2364
9. Conatus Pharmaceuticals Initiates a Second Phase 2 Clinical Trial for the Treatment of Hepatitis
10. ProFibrix Initiates Phase II Clinical Trial of its Lead Topical Hemostat Product Fibrocaps(TM)
11. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... , May 22, 2015 AcelRx Pharmaceuticals, ... focused on the development and commercialization of innovative therapies ... announced that interim chief executive officer Howie Rosen ... and chief financial officer Tim Morris will ... of the two presentations are as follows: ...
(Date:5/21/2015)... , May 21, 2015 ... has announced the addition of the ... (Ankle Replacement, Digit Replacement, Elbow Replacement, Hip ... to 2019" report to their offering. ... knee replacement was valued at $4,470.9 million ...
(Date:5/21/2015)... DUBLIN , May 21, 2015 ... has announced the addition of the "North ... & Graft), by Application (Surgical Wound, & Ulcer), ... Forecast to 2019" report to their offering. ... wound care market is estimated to grow at ...
Breaking Medicine Technology:AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences In June 2North American Joint Reconstruction Market 2015-2019 - Zimmer Holdings, DePuy Synthes Companies, Stryker, Biomet & Smith & Nephew Dominates the $4.4 Billion Market 2North American Active Wound Care Market 2015-2019 with Smith and Nephew, Molyncke HealthCare & ConvaTec Dominating 2
... , GENEVA, Switzerland, December 14 ... Meeting was held,in Bermuda on 7th December. In excess of ... and overwhelmingly approved all the resolutions,put forward. , ... Shortt of Galmoy,as the new Director of Corporate Communications. In ...
... , , STUART, ... LBMH) is pleased to announce the addition of Mr. Joseph Farish ... Farish is s graduate of the University of Florida (Bachelor of ... has been a member of the Florida Bar for more than ...
Cached Medicine Technology:Calcitech Holds Annual General Meeting 2Liberator Medical Strengthens its Board of Directors with the Addition of Mr. Joseph Farish and Mr. Robert S. Cuillo 2Liberator Medical Strengthens its Board of Directors with the Addition of Mr. Joseph Farish and Mr. Robert S. Cuillo 3Liberator Medical Strengthens its Board of Directors with the Addition of Mr. Joseph Farish and Mr. Robert S. Cuillo 4
(Date:5/22/2015)... 2015 Memorial Day weekend is typically considered ... is offering some tips to help promote safe travel. , ... be 383 traffic fatalities this Memorial Day weekend. Amica is ... Traffic Safety Association: , , Always ... wearing a seatbelt, whether they’re driving or riding along as ...
(Date:5/22/2015)... Philadelphia, PA (PRWEB) May 22, 2015 According ... as a hub for drug related death, totaling almost 2,500 ... number, as reported by state officials, totals 2,489 deaths stemming ... numbers work out, Pennsylvania loses seven people every day to ... Philadelphia has been singled out as one of the most ...
(Date:5/22/2015)... 22, 2015 A Phase 3 ... American Society of Clinical Oncology (ASCO)’s annual meeting ... rates for those patients who received bevacizumab in ... pemetrexed/cisplatin. Bevacizumab (Avastin® Genentech, Inc.) is an antibody ... is already routinely used to treat many other ...
(Date:5/22/2015)... New York, NY (PRWEB) May 22, 2015 ... of Multifamily Housing, Marc Zuluaga, has been selected by ... innovative engineering. The award winners are featured in the ... given to 40 building industry professionals age 40 and ... to the building community, as well as in other ...
(Date:5/22/2015)... Puritan Medical Products, a Maine ... diagnostic, environmental, and forensics industries celebrates 96 years ... the US. At a time when countless manufacturing ... Puritan remains committed to designing and manufacturing their ... facility. , Since 1919, Puritan has focused on ...
Breaking Medicine News(10 mins):Health News:Amica Has 4 Road Safety Tips for Memorial Day Weekend 2Health News:Philadelphia Ranks Among the Tops Cities in Penn. for Drug Deaths 2Health News:Mesothelioma Research Organization Excited About Imminent Improvement to Standard of Care 2Health News:Steven Winter Associates’ Marc Zuluaga Earns Innovative Engineering Award 2Health News:Maine Swab Company Celebrates 96 Years of American-made Products 2
... L. Myers ... Kids, WASHINGTON, Jan. 24 The following statement,was issued ... A new global survey released by the U.S. Centers for ... and even higher,rates of exposure to secondhand smoke, among children ...
... Reproductive Science Center to Open Melrose, Massachusetts Location in ... ... Science Center,of New England announces the opening of a new office in ... and Malden. The,Melrose office, located at 830 Main Street, Suite 207, will ...
... Inc.,(Nasdaq: OMCL ), a leading provider of system solutions to ... discuss,the company,s fourth quarter financial results., What: ... When: January 31, 2008, 3:00 p.m. PST ... Rob ...
... inflammation-induced colon cancer in its tracks , Individuals ... increased risk of developing colon cancer. New data generated ... identified a central role for the soluble factor TNF-alpha ... which inflammation of the bowel was induced by administration ...
... life span of mice with inherited Lou Gehrig,s disease ... that nearly doubles the life span of mice with ... University of Iowa researchers, who made the finding after ... , The study results, published online Jan. 24 in ...
... RMD ),announced today that on Thursday, February 7, ... of fiscal year 2008, ended December 31,2007. ResMed will ... and will host a conference call to review its ... call is scheduled to begin at 1:30 p.m. Pacific ...
Cached Medicine News:Health News:New CDC Global Survey Finds Tobacco Taking Massive Toll on World's Children 2Health News:New CDC Global Survey Finds Tobacco Taking Massive Toll on World's Children 3Health News:Leading IVF Practice to Open 11th New England Location 2Health News:Omnicell Schedules Fourth Quarter Earnings Call 2Health News:JCI table of contents: Jan. 24, 2008 2Health News:JCI table of contents: Jan. 24, 2008 3Health News:JCI table of contents: Jan. 24, 2008 4Health News:JCI table of contents: Jan. 24, 2008 5Health News:JCI table of contents: Jan. 24, 2008 6Health News:JCI table of contents: Jan. 24, 2008 7Health News:Surprise in Lab Helps ID Drug to Fight ALS 2Health News:RESMED to Webcast Second Quarter 2008 Earnings Conference Call 2
... superb field flatness, high UV transmission ... extra long working distances, these objectives ... with inverted microscopes. Because of their ... ELWD DM,objectives can be used universally ...
Inquire...
... Axiovert 40 inverted microscope ... have ever expected from a microscope in this ... quality, and functionality. Axiovert 40 has been designed ... as possible thus increasing the efficiency of ...
... is an advanced inverted microscope ... exclusive CFI60 optical system yields ... aperatures and longer working distances. ... to take full advantage of ...
Medicine Products: